



MESCO PHARMACEUTICALS LIMITED

Corporate Identity No. L24111UR1986PLC015895

Corporate Identity No. L24111UR1986PLC015895

Regd. Office: Upper Kesalton, Tallital, Nainital- 263 001, Uttarakhand. Tel: 9871862796

W: www.mescopharma.com E-mail: nsparameswaran@mescosteel.com

MPL/ 33/QTR-3/ 2018-19

February 13, 2019

Bombay Stock Exchange
Department of Investor Services
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai-400001

Sub: Outcome of Board Meeting held on 13th February, 2019

Dear Sir,

Pursuant to Regulations 30 and 33 of SEBI (LODR) Regulations, 2015 please find enclosed the following documents duly considered and approved by the Board of Directors in their Board Meeting held on Wednesday, 13th February, 2019 at New Delhi commenced at 02:00 pm and concluded at 2:50 p.m.

1. Standalone unaudited Financial Results for the quarter ended on 31st December, 2018
2. Limited Review Report for the quarter ended on 31st December, 2018

This is for your information and records.

Thanking you,

For Mesco Pharmaceuticals Limited

(Director)

Encl: as above

MESCO PHARMACEUTICALS LTD

CIN : L24111RJ98691015895

REGD. OFFICE : UPPER RESALTON, TALLITAL, NANITAL-263 601, UTTARAKHAND

Tel : 011-41587085, E-mail : nparameswaran@mescoindia.com

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 31st Dec 2018

(In Rs.)

Sl No	PARTICULARS	Quarter Ended				Nine month ended		Year Ended
		31.12.2018	30.09.2018	31.12.2017	31.12.2018	31.12.2017	31.03.2018	
		UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	AUDITED	
1	Income from Operations							
	(a) Net Sales/ Income from operations	-	-	-	-	-	-	
	(b) Other Income	-	-	-	-	-	-	
2	Total Income from Operations (net)	-	-	-	-	-	-	
	Expenses							
	(a) Cost of Material Consumed	-	-	-	-	-	-	
	(b) Change in Inventories of finished goods and work in progress	-	-	-	-	-	-	
	(c) Employees Benefits Expenses	-	-	74,194.00	-	230,581.00	305,581.00	
	(d) Depreciation and Amortisation expenses	-	-	-	-	-	-	
	(e) Finance Cost	-	-	-	-	-	150.00	
	(f) Other Expenses	45,728.00	3,571,752.00	32,792.00	3,916,680.00	513,319.20	567,759.00	
	Total Expenses	45,728.00	3,571,752.00	106,986.00	3,916,680.00	743,930.20	873,490.00	
3	Profit/(Loss) Before Exceptional Items and Tax	(45,728.00)	(3,571,752.00)	(106,986.00)	(3,916,680.00)	(743,930.20)	(873,490.00)	
	Exceptional Items	-	-	-	-	-	-	
4	Profit/(Loss) before Tax	(45,728.00)	(3,571,752.00)	(106,986.00)	(3,916,680.00)	(743,930.20)	(873,490.00)	
	(a) Current Tax	-	-	-	-	-	-	
	(b) Deferred Tax	-	-	-	-	-	-	
	(c) Tax expense relating to Earlier years	-	-	-	-	-	-	
5	Profit for the Period	(45,728.00)	(3,571,752.00)	(106,986.00)	(3,916,680.00)	(743,930.20)	(873,490.00)	
	Other Comprehensive Income							
	If any							
	Total Comprehensive Income for the Period	(45,728.00)	(3,571,752.00)	(106,986.00)	(3,916,680.00)	(743,930.20)	(873,490.00)	
6	Paid up Equity Share Capital	197,381,000.00	197,381,000.00	197,381,000.00	197,381,000.00	197,381,000.00	197,381,000.00	
	(Face value Rs. 10/- per Equity Share)							
7	Earning per share (before and after extraordinary items) (Rs.10- each)	(0.00)	(0.18)	(0.01)	(0.19)	(0.04)	(0.04)	
	Basic (Rs.)	(0.00)	(0.18)	(0.01)	(0.19)	(0.04)	(0.04)	
	Diluted (Rs.)	(0.00)	(0.18)	(0.01)	(0.19)	(0.04)	(0.04)	

Notes :

- The above Results, have been reviewed and recommended by the Audit Committee and approved by the Board of Directors at their respective Board Meeting held on 13.02.2019
- The Statutory Auditors of the Company have carried out Limited Review of the above Results.
- Figures for the previous period have been re-classified, re-grouped/ re-arranged wherever necessary.
- There were no manufacturing activities in the company during the period under consideration

PLACE : NEW DELHI
DATED 13.02.2019

Director



FOR AND ON BEHALF OF THE BOARD OF
MESCO PHARMACEUTICALS LIMITED

Sangram Paul & Co.

S.K. Paul, F.C.A.

Chartered Accountant

Chartered Accountants

Plot No.-754/15, Jayadev Vihar, Bhubaneswar-751 013

Phone : 0674-2360863, Mob. : 9337116878

Review Report to MESCO PHARMACEUTICALS LIMITED

We have reviewed the accompanying statement of Unaudited financial results of MESCO PHARMACEUTICALS LIMITED for the quarter and nine months ended December 31, 2018, being submitted by the company pursuant to the requirements of Regulation 33 of SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, read with SEBI circular CIR/CFD/FAC/62/2016 dated July 5, 2016.

This statement is the responsibility of the Company's Management and approved by the Board of Directors has been prepared in accordance with Indian Accounting Standard ("IND-AS") prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles general accepted in India. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of Unaudited Financial Results prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ("Ind AS") prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Circular No: CIR/CFD/FAC/62/2016 dated 5th July, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Sangram Paul & Co.
Chartered Accountants
Firm Registration No. 308001E

S.K. Paul
Proprietor
M. No.: - 013015



Date: 13th February, 2019
Place: New Delhi